Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Blind, Randomized, Placebo-Controlled, Parallel, Time-Lagged, Ascending, Multi-Centre, Multiple-Dose Study to Measure the Magnitude and Time Course of the Effect of FTY720 on FEV1 and Other Pulmonary Function Tests (FVC, FEF25-75%, and FEV1/FVC) in Patients With Moderate Asthma.

Trial Profile

A Double-Blind, Randomized, Placebo-Controlled, Parallel, Time-Lagged, Ascending, Multi-Centre, Multiple-Dose Study to Measure the Magnitude and Time Course of the Effect of FTY720 on FEV1 and Other Pulmonary Function Tests (FVC, FEF25-75%, and FEV1/FVC) in Patients With Moderate Asthma.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 25 Jul 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fingolimod (Primary)
  • Indications Asthma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Novartis; Novartis Pharma A.G.

Most Recent Events

  • 16 Nov 2011 Actual initiation date changed from Sep 2008 to May 2008 as reported by European Clinical Trials Database record.
  • 16 Nov 2011 New source identified and integrated (European Clinical Trials Database: EudraCT2007-001714-16)
  • 13 Apr 2010 Results presented at the 62nd Annual Meeting of the American Academy of Neurology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top